Form 8-K - Current report:
SEC Accession No. 0001193125-25-183796
Filing Date
2025-08-20
Accepted
2025-08-20 08:50:42
Documents
20
Period of Report
2025-08-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d947368d8k.htm   iXBRL 8-K 65804
2 EX-2.1 d947368dex21.htm EX-2.1 640086
3 EX-2.2 d947368dex22.htm EX-2.2 40500
4 EX-2.3 d947368dex23.htm EX-2.3 53468
5 EX-99.1 d947368dex991.htm EX-99.1 910265
6 EX-99.2 d947368dex992.htm EX-99.2 25329
7 EX-99.3 d947368dex993.htm EX-99.3 25301
11 GRAPHIC g947368g0819233955221.jpg GRAPHIC 3969
12 GRAPHIC g947368g0819233955913.jpg GRAPHIC 5316
  Complete submission text file 0001193125-25-183796.txt   2244482

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA mura-20250820.xsd EX-101.SCH 2867
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE mura-20250820_lab.xml EX-101.LAB 17909
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mura-20250820_pre.xml EX-101.PRE 11245
22 EXTRACTED XBRL INSTANCE DOCUMENT d947368d8k_htm.xml XML 3609
Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41837 | Film No.: 251234048
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)